“The team focused on cell and gene therapy at ADVI has the expertise that is required and necessary to understand the nuances of bringing products to market.”
Successful cell or gene therapy coverage and reimbursement requires a nuanced, multidisciplinary approach. It also requires deep knowledge in policy, pricing, and access – oftentimes alongside the right partner.
ADVI Health is a trailblazer with critical commercial launch preparation for cell and gene therapies that help treat, prevent, or cure a wide array of untreatable and difficult-to-treat diseases. We help our clients navigate the federal and state policy landscape, highlight unique value drivers, and advocate to critical stakeholders across the healthcare landscape and pride ourselves in the ability to achieve positive results.
We are your go-to partner for strategy, policy updates, data analytics and value economics in cell and gene therapies, rare and ultra-rare diseases, and oncology therapeutics, devices, and diagnostics.
Explore the latest resources and up-to-date information on cell and gene, implications for the industry, and insights on recent updates.
Latest News
“As the cell and gene therapy sector evolves, we are excited to continue supporting clients in new therapies and indications that revolutionize medicine. At ADVI, we have the privilege of working with talented clients to enable patient access in a dynamic policy landscape.”
Alicia Silver, MPP, Senior Director, Emerging Therapies
Seize The Opportunity
Submit an RFP
Submit an RFP and let’s determine how our team of experts can support your business.
Market Access
Alan
He
Director, Market Access 
Steve
Carter
Vice President, Pricing and Market Access 
Michael
Barlow
Senior Advisor 
Louis Jacques, MD
Senior Advisor
Michael Kolodziej, MD, FACP
Senior Advisor
Norris Turner, PharmD, PhD
Senior Advisor
Shefali Shah, MPH
Senior Advisor